No Data
No Data
Nurix Therapeutics Presents Positive Results From the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Express News | Nurix Therapeutics Expands Its Board of Directors With the Addition of Drug Commercialization Expert Anil Kapur
Press Release: Nurix Therapeutics Expands Its Board of Directors With the Addition of Drug Commercialization Expert Anil Kapur
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Raises Target Price to $35
Nurix Therapeutics Price Target Raised to $35 From $30 at Oppenheimer
J.P. Morgan Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Cuts Target Price to $31